David M. Johnson - Jun 4, 2021 Form 4/A - Amendment Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for David M. Johnson
Stock symbol
ZNTL
Transactions as of
Jun 4, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
12/17/2021, 04:57 PM
Date Of Original Report
Jun 8, 2021
Next filing
Oct 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +7.5K +8.44% $0.00 96.4K Jun 4, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +22.5K $0.00 22.5K Jun 4, 2021 Common Stock 22.5K $52.25 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to correct the number of RSUs granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 7,500 RSUs on June 4, 2021, to vest on the first to occur of (a) June 4, 2022 or (b) the next occurring annual meeting of the Company's stockholders.
F2 Due to the error described above, the Reporting Person's Form 4 filed on October 4, 2021 incorrectly reported that the number of shares held by the Reporting Person was 80,959 shares of Common Stock.
F3 This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date.